132 related articles for article (PubMed ID: 10201970)
1. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.
Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ
J Immunol; 1999 Apr; 162(8):4373-6. PubMed ID: 10201970
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
3. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
5. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
6. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
7. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM; Kerkvliet NI
J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
[TBL] [Abstract][Full Text] [Related]
8. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
9. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD.
Pals ST; Radaszkiewicz T; Gleichmann E
J Immunol; 1984 Apr; 132(4):1669-78. PubMed ID: 6230390
[TBL] [Abstract][Full Text] [Related]
10. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
[TBL] [Abstract][Full Text] [Related]
11. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.
Paz Morante M; Briones J; Canto E; Sabzevari H; Martino R; Sierra J; Rodriguez-Sanchez JL; Vidal S
Clin Exp Immunol; 2006 Jul; 145(1):36-43. PubMed ID: 16792671
[TBL] [Abstract][Full Text] [Related]
12. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL.
Hadley GA; Bartlett ST; Via CS; Rostapshova EA; Moainie S
J Immunol; 1997 Oct; 159(8):3748-56. PubMed ID: 9378961
[TBL] [Abstract][Full Text] [Related]
13. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
14. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
Lee S; Chong SY; Lee JW; Kim SC; Min YH; Hahn JS; Ko YW
Bone Marrow Transplant; 1997 Nov; 20(10):883-8. PubMed ID: 9404931
[TBL] [Abstract][Full Text] [Related]
15. Unconventional NK1.1(-) intermediate TCR cells as major T lymphocytes expanding in chronic graft-versus-host disease.
Miyakawa R; Miyaji C; Watanabe H; Yokoyama H; Tsukada C; Asakura H; Abo T
Eur J Immunol; 2002 Sep; 32(9):2521-31. PubMed ID: 12207336
[TBL] [Abstract][Full Text] [Related]
16. Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 cannot be restored by increased TCR signaling.
Shier P; Ngo K; Fung-Leung WP
J Immunol; 1999 Nov; 163(9):4826-32. PubMed ID: 10528183
[TBL] [Abstract][Full Text] [Related]
17. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
[TBL] [Abstract][Full Text] [Related]
18. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
[TBL] [Abstract][Full Text] [Related]
19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
20. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.
Zhai Y; Meng L; Busuttil RW; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 2003 Mar; 170(6):3024-8. PubMed ID: 12626556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
